The results of this study showed that KRAS and NRAS mutataions are usually present in the large majority of tumor cells, whereas BRAF and PIK3CA mutations often affect a limited, subclonal fraction of tumor cells [227]. This evidence concerns the gene KRAS and neoplasm.